Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Letter
  • Published:

MULTIPLE MYELOMA, GAMMOPATHIES

Treatment outcomes of triple class refractory multiple myeloma: a benchmark for new therapies

Leukemia volume 36, pages 877–880 (2022)Cite this article

Subjects

To the editor:

The outcomes of patients with newly diagnosed multiple myeloma (MM) continue to improve with a deeper understanding of disease pathobiology, expansion of the therapeutic armamentarium and improvements in supportive care [1]. The development of proteasome inhibitors (PIs), immunomodulatory agents (IMiDs), and anti-CD38 monoclonal antibodies (CD38Moabs) and their uptake into earlier lines of therapy has revolutionized the field producing rapid, deep, and durable disease control. However, MM almost invariably relapses and ultimately patients die from refractory disease [2]. The management of triple class refractory (TCR) MM (refractory to PIs, IMIDs, and CD38Moabs) is a modern therapeutic challenge [3]. Novel classes of agents such as exportin-1 inhibitors, chimeric antigen receptor T cells, T cell redirecting antibodies, and antibody-drug conjugates are in various stages of clinical development and regulatory approval. Assessment of their relative impact and incremental value in the TCR setting is impaired by limited evidence from prospective randomized trials or benchmarks for therapeutic outcomes when available drugs are deployed in this setting. We sought to characterize and delineate therapeutic outcomes of TCR MM.

This is a preview of subscription content, access via your institution

Access options

Buy this article

  • Purchase on SpringerLink
  • Instant access to the full article PDF.

USD 39.95

Prices may be subject to local taxes which are calculated during checkout

Fig. 1: Outcomes of patients with triple class refractory multiple myeloma.

References

  1. Kumar SK, Dispenzieri A, Lacy MQ, Gertz MA, Buadi FK, Pandey S, et al. Continued improvement in survival in multiple myeloma: changes in early mortality and outcomes in older patients. Leukemia. 2014;28:1122–8.

    Article  CAS  Google Scholar 

  2. Bolli N, Avet-Loiseau H, Wedge DC, Van Loo P, Alexandrov LB, Martincorena I, et al. Heterogeneity of genomic evolution and mutational profiles in multiple myeloma. Nat Commun. 2014;5:2997.

    Article  Google Scholar 

  3. Gandhi UH, Cornell RF, Lakshman A, Gahvari ZJ, McGehee E, Jagosky MH, et al. Outcomes of patients with multiple myeloma refractory to CD38-targeted monoclonal antibody therapy. Leukemia. 2019. http://www.nature.com/articles/s41375-019-0435-7.

  4. Kumar S, Paiva B, Anderson KC, Durie B, Landgren O, Moreau P, et al. International Myeloma Working Group consensus criteria for response and minimal residual disease assessment in multiple myeloma. Lancet Oncol. 2016;17:e328–46.

    Article  Google Scholar 

  5. Raje N, Berdeja J, Lin Y, Siegel D, Jagannath S, Madduri D, et al. Anti-BCMA CAR T-Cell Therapy bb2121 in Relapsed or Refractory Multiple Myeloma. N. Engl J Med. 2019;380:1726–37.

    Article  CAS  Google Scholar 

  6. Munshi NC, Anderson LDJR, Shah N, Madduri D, Berdeja J, Lonial S, et al. Idecabtagene vicleucel in relapsed and refractory multiple myeloma. N. Engl J Med. 2021;384:705–16.

    Article  CAS  Google Scholar 

  7. Chari A, Vogl DT, Gavriatopoulou M, Nooka AK, Yee AJ, Huff CA, et al. Oral selinexor-dexamethasone for triple-class refractory multiple myeloma. N. Engl J Med. 2019;381:727–38.

    Article  CAS  Google Scholar 

  8. Richardson PG, Oriol A, Larocca A, Bladé J, Cavo M, Rodriguez-Otero P, et al. Melflufen and dexamethasone in heavily pretreated relapsed and refractory multiple myeloma. J Clin Oncol. 2021;39:757–67.

    Article  CAS  Google Scholar 

  9. Lonial S, Lee HC, Badros A, Trudel S, Nooka AK, Chari A, et al. Belantamab mafodotin for relapsed or refractory multiple myeloma (DREAMM-2): a two-arm, randomised, open-label, phase 2 study. Lancet Oncol. 2020;21:207–21.

    Article  CAS  Google Scholar 

  10. Richardson PG, Jagannath S, Chari A, Vogl DT, Dimopoulos MA, Moreau P, et al. Overall survival with oral selinexor plus low-dose dexamethasone versus real-world therapy in triple-class-refractory multiple myeloma. eJHaem. 2021;2:48–55.

    Article  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Division of Hematology Oncology, University of Alabama at Birmingham, Birmingham, AL, USA

    Susan Bal, Kelly N. Godby, Smith Giri & Luciano J. Costa

  2. University Hospitals Cleveland Medical Center, Cleveland, OH, USA

    Ehsan Malek

  3. University of Texas Southwestern Medical Center, Dallas, TX, USA

    Ankit Kansagra

  4. Levine Cancer Institute/Atrium Health, Charlotte, NC, USA

    Saad Z. Usmani

  5. Washington University in St. Louis, St Louis, MO, USA

    Ravi Vij

  6. Vanderbilt University, Nashville, TN, USA

    Robert F. Cornell

  7. Duke University, Durham, NC, USA

    Yubin Kang

  8. University of Vermont, Burlington, VT, USA

    Elvira Umyarova

  9. Medical College of Wisconsin, Milwaukee, WI, USA

    Saurabh Chhabra & Parameswaran Hari

  10. Stanford University, Stanford, CA, USA

    Michaela Liedtke

  11. University of Wisconsin, Carbone Cancer Center, Madison, WI, USA

    Natalie S. Callander

  12. Department of Hematology, Mayo Clinic Rochester, Rochester, MN, USA

    Shaji Kumar

Authors
  1. Susan Bal
    View author publications

    Search author on:PubMed Google Scholar

  2. Ehsan Malek
    View author publications

    Search author on:PubMed Google Scholar

  3. Ankit Kansagra
    View author publications

    Search author on:PubMed Google Scholar

  4. Saad Z. Usmani
    View author publications

    Search author on:PubMed Google Scholar

  5. Ravi Vij
    View author publications

    Search author on:PubMed Google Scholar

  6. Kelly N. Godby
    View author publications

    Search author on:PubMed Google Scholar

  7. Robert F. Cornell
    View author publications

    Search author on:PubMed Google Scholar

  8. Yubin Kang
    View author publications

    Search author on:PubMed Google Scholar

  9. Elvira Umyarova
    View author publications

    Search author on:PubMed Google Scholar

  10. Smith Giri
    View author publications

    Search author on:PubMed Google Scholar

  11. Saurabh Chhabra
    View author publications

    Search author on:PubMed Google Scholar

  12. Michaela Liedtke
    View author publications

    Search author on:PubMed Google Scholar

  13. Natalie S. Callander
    View author publications

    Search author on:PubMed Google Scholar

  14. Parameswaran Hari
    View author publications

    Search author on:PubMed Google Scholar

  15. Shaji Kumar
    View author publications

    Search author on:PubMed Google Scholar

  16. Luciano J. Costa
    View author publications

    Search author on:PubMed Google Scholar

Contributions

The authors confirm contribution to the paper as follows: study conception and design: all authors. Data collection: all authors. Analysis and interpretation of results: all authors, draft manuscript preparation: SB and LC. All authors reviewed the results, critically revised it for important intellectual content and approved the final version of the manuscript.

Corresponding author

Correspondence to Susan Bal.

Ethics declarations

Competing interests

EhM: Consultancy and Speakers Bureau (Takeda, Celgene, Amgen, Janssen); ML: Consultancy (Amgen/Onyx), Honoraria (Amgen/Onyx, Pfizer, Prothena, Takeda), Research Funding (Amgen/Onyx, BlueBirdBio, Celgene, Genentech/Roche, Gilead, Pfizer, Prothena, Takeda), Membership on an entity’s Board of Directors or advisory committees (Caelum, Pfizer, Prothena, Takeda); PH: Consultancy and Research Funding (Amgen, Celgene), Honoraria (Celgene); RV: Honoraria (Celgene, Bristol Myers Squibb, Takeda, Amgen, Janssen, Karyopharma, Jazz), Research Funding (Celgene, Bristol Myers Squibb, Takeda); SU: Consultancy (Abbvie, Amgen, Celgene, Genmab, Merck, MundiPharma, Seattle Genetics), Research Funding (Amgen, BMS, Celgene, Janssen, Merck, Pharmacyclics, Takeda), Membership on an entity’s Board of Directors or advisory committees (Sanofi); ShK: Consultancy (AbbVie, Celgene, Janssen, Kite Pharma, Merck, Takeda); LC: Honoraria (Amgen, Celgene, AbbVie), Research Funding (Amgen, Celgene, Janssen). SB has received research funding from Amyloid Foundation. SG is supported in part by the Walter B. Frommeyer Fellowship in Investigative Medicine at the University of Alabama at Birmingham and reports receiving research funding from Carevive Systems and Pack Health. SC: Research Funding: Amgen, Janssen, Sanofi; Honorarium: Glaxo Smith Kline. Other authors do not have any conflicts of interest to disclose.

Additional information

Publisher’s note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Bal, S., Malek, E., Kansagra, A. et al. Treatment outcomes of triple class refractory multiple myeloma: a benchmark for new therapies. Leukemia 36, 877–880 (2022). https://doi.org/10.1038/s41375-021-01471-3

Download citation

  • Received:

  • Revised:

  • Accepted:

  • Published:

  • Version of record:

  • Issue date:

  • DOI: https://doi.org/10.1038/s41375-021-01471-3

This article is cited by

Search

Advanced search

Quick links